Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Tau​2 = 0.80, I​2 = 66.9%, p = 0.12 Early treatment 63% 0.37 [0.10-1.32] 3/1,467 22/1,472 63% improvement Wong (PSM) 68% 0.32 [0.23-0.45] death 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 68% 0.32 [0.23-0.45] 0/991 0/3,952 68% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 54% 0.46 [0.26-0.80] 3/3,444 22/6,409 54% improvement 5 paxlovid COVID-19 studies c19early.com/pl May 2022 Tau​2 = 0.24, I​2 = 74.9%, p = 0.006 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control
Paxlovid COVID-19 studies. Pfizer has denied access to Paxlovid for an independent RCT. Recent:
Wong
Pfizer
Ledford.
Paxlovid has been officially adopted for early treatment in 7 countries. Submit updates/corrections.
May 24
Early Yip et al., SSRN (Preprint)
death/ICU, ↓19.0%, p=0.45
Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients
Details   Propensity score weighted retrospective of 93,883 outpatients in Hong Kong, 5,808 treated with molnupiravir and 4,921 treated with paxlovid, showing higher hospitalization and higher combined mortality/mechanical ventilation/ICU admission..
May 20
Late Wong et al., medRxiv, doi:10.1101/2022.05.19.22275291 (Preprint)
death, ↓68.0%, p<0.0001
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
Details   PSM retrospective 40,776 hospitalized patients in Hong Kong, showing lower mortality with paxlovid treatment.
Apr 29
PrEPPEP Pfizer News Release (News)
cases, ↓37.0%, p=0.05
Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use
Details   PEP RCT showing lower risk of cases with treatment, without statistical significance. The group sizes and event counts have not been provided.
Apr 4
News Ledford et al., Nature, doi:10.1038/d41586-022-00919-5 (News)
news
African clinical trial denied access to key COVID drug Paxlovid
Details   News reporting that Pfizer denied access to Paxlovid for an independent trial.
Feb 16
Early Hammond et al., New England Journal of Medicine, doi:10.1056/NEJMoa2118542
death, ↓96.0%, p=0.0005
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Details   EPIC-HR RCT, 1,039 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 1,046 control patients, showing significantly lower mortality and hospitalization with treatment. NCT04960202.
Dec 14
2021
Early Pfizer Press Release (News)
hosp., ↓70.1%, p=0.05
Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death
Details   EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513.
Nov 30
2021
In Vitro Ullrich et al., bioRxiv, doi:10.1101/2021.11.28.4702264 (Preprint) (In Vitro)
In Vitro
Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332
Details   In Vitro study showing that PF-07321332 maintains efficacy against variants C.37 lambda, B.1.1.318, B.1.2, B.1.351 beta, and P.2 zeta.
Nov 5
2021
Animal Abdelnabi et al., bioRxiv, doi:10.1101/2021.11.04.467077 (Preprint)
animal study
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Details   In Vitro and hamster study showing paxlovid component PF-07321332 effective against four variants of concern, inibits replication of the alpha variant in primary human airway epithelial cells, protected Syrian hamsters against intranasal ..
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit